Organogenesis Holdings Inc. provided earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expects net revenue of between $465 million and $490 million, representing a decrease of approximately 1% to an increase of 5% year-over-year, and 2% to 7% on an adjusted basis, as compared to net revenue of $467.4 million for the year ended December 31, 2021. Net income in a range of approximately $26 million to $36 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.58 USD | +3.20% | +4.45% | -36.92% |
May. 13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
May. 10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.92% | 342M | |
+23.13% | 46.93B | |
+37.49% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+45.05% | 14.15B | |
+32.23% | 12.53B | |
-6.56% | 11.36B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022